CHChris Hinds

Chris Hinds

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chris Hinds has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Early Detection of Neurodegenerative diseases (EDoN) Initiative: protocol for a meta-cohort study (Preprint)

    by Tim Whitfield, Kieran Wing, Sharandeep Bhogal, Chris Hinds, David Llewellyn, Nick Bass, Kristi Ho, Claire Lancaster, Rachel Morrell, Josephine Shaw, et al.

    BACKGROUND Conventional diagnostic tests for dementia are invasive, expensive, and/or not scalable. Blood-based biomarkers are beginning to enter clinical practice but are not yet widely available, and do not currently provide differential-diagnostic information about non-Alzheimer’s disease pathologies. The Early Detection of Neurodegenerative diseases (EDoN) Initiative is investigating the potential utility of digital measures to support the early detection of dementia at scale. OBJECTIVE The ultimate objective is to evaluate the utility of the included wearables/apps as early detection markers for dementia. This will be achieved by analyzing relationships between wearables/apps and dementia outcomes, including both hard endpoints (i.e., clinical progression) as well as surrogate markers (e.g., cognitive decline). METHODS Four international cohorts (UK, Australia, USA) collected longitudinal digital, clinical and biomarker data from healthy controls and people at elevated risk of cognitive decline. Participants used ≥2 of the following wearables/apps: electroencephalographic sleep headband, wrist-worn activity tracker, cognitive testing smartphone app, and/or passive smartphone monitoring app. RESULTS Across the four cohorts, 436 individuals were enrolled, including 149 (34%) healthy controls, 166 (38%) patients with subjective cognitive decline (SCD), 114 (26%) patients with mild cognitive impairment, and 7 (2%) patients with very mild dementia. Fifty participants (11%) withdrew during the study, while 386 (89%) participants completed the study. CONCLUSIONS The harmonized EDoN data will be made available for sharing via a cloud-based trusted research environment, driving progress in the field.

  • Open Access

    Remote assessment of functional impairment in Alzheimer’s disease: results of the RADAR‐AD study

    by Marijn Muurling, Casper de Boer, Srinivasan Vairavan, Jelena Curcic, Gaetano Scebba, Alankar Atreya, Chris Hinds, Pauline Conde, Margarita Grammatikopoulou, Ioulietta Lazarou, et al.

    Background: Remote monitoring technologies (RMTs), such as smartphone apps and smartwatches, are changing the way functional and cognitive performance are measured in Alzheimer’s disease (AD). Due to their sensitivity, objectivity, and the option of long‐term and continuous measurement, RMTs have the potential to detect a subtle decline in the earliest stages of AD. Here, we present the results of the European RADAR‐AD project (Remote Assessment of Disease and Relapse – Alzheimer’s disease), which aims to test feasibility, acceptability and validity of RMT measures across all stages of AD, from cognitively normal to mild dementia.Method: Four study groups (amyloid negative healthy controls, and amyloid positive preclinical AD, prodromal AD, mild‐to‐moderate AD) were included in this cross‐sectional study (N = 175). During 8 weeks, participants wore two activity trackers (Fitbit and Axivity) measuring physical activity, heart rate and sleep continuously, and used two interactive smartphone apps (Mezurio and Altoida’s research algorithm: DNS‐MCI) measuring cognition daily/weekly. At baseline, participants underwent extensive neuropsychological, physical examinations, and did two sensor‐based tests (banking app and walk test). Features were extracted for all RMTs (Figure 1) and compared across groups using ANCOVA, with adjustment for relevant confounders. This study is part of an ongoing investigation into high‐end multimodal analyses for real‐world functional performance of continuous RMT data streams.Result: Compliance was high, but decreased with cognitive impairment (feasibility). User experience did not differ between groups but was lower for smartwatches compared to interactive smartphone apps (Table 1) (acceptability). Various individual sensors discriminated symptomatic AD participants from asymptomatic participants (pThis work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking (grant No 806999) and their associated partners. www.imi.europa.eu. This communication reflects the views of the RADAR‐AD consortium and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein.

  • Open Access

    A multimodal digital biomarker of functional deficits in early‐stage Alzheimer’s disease: results of the RADAR‐AD study

    by Srinivasan Vairavan, Manuel Lentzen, Marijn Muurling, Casper de Boer, Alankar Atreya, Jelena Curcic, Chris Hinds, Pauline Conde, Margarita Grammatikopoulou, Gaetano Scebba, et al.

    Background: Remote monitoring technologies (RMTs), such as smartphone apps, smartwatches, and in‐home sensors, are rapidly changing the way functional and cognitive performance is measured in Alzheimer’s disease (AD) patients. Here, we present results from the European RADAR‐AD study on the use of multimodal data streams for the identification of functional deficits across all syndromic stages of AD.Method: Four study groups (Healthy controls (HC), preclinical AD (pre. AD), prodromal AD (pro. AD), and mild AD) were included in this cross‐sectional study. The RMT features (gait measures from Timed up and Go (TUG), Dual Task Effect (DTE) using physilog, acoustic features from Speech task in Mezurio, neurocognitive function using Altoida, managing finances with Banking app) with in‐clinic neuropsychological (NP) tests, activities of daily living with Amsterdam IADL and demographics (age, gender, education years) were analyzed for different combinations of the multimodal digital biomarker of disease stage in AD across different pairwise comparisons. The analysis includes data from 175 participants (HC = 67, Pre.AD = 26, Pro.AD = 50, Mild AD = 32) collected for 8 weeks. An extreme gradient boosting (XGBoost) machine learning model was trained to obtain a multimodal biomarker of AD disease stage with repeated cross‐validation (5‐fold with 4 repeats) (Figure 1). This investigation is part of the ongoing RADAR‐AD study.Result: The multimodal combination of RMTs achieved a mean AUC of > 0.60 in all pairwise comparisons with a mean AUC > 0.65 for HC vs (Pre.AD, Pro.AD and Mild) (Figures 2 and 3). The addition of NP tests increases the performance considerably across all pairwise comparisons except HC vs Pre.AD.Conclusion: Our results highlight the advantage of combining RMTs to identify functional deficits in the early stage of AD. In particular, in prodromal and mild AD patients, a combined signal shows much more strength compared to individual tests. This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking (grant No 806999). www.imi.europa.eu. This communication reflects the views of the RADAR‐AD consortium and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein.


  • Open Access

    The Early Detection of Neurodegenerative diseases initiative: emerging insights from the initial implementation of a digital toolkit

    by Tim Whitfield, Sharandeep Bhogal, Kieran Wing, Simon Bond, Rachel Morrell, Nicholas Bass, Leonidas Chouliaras, Sarah Wilson, Emily Beswick, Sarah Slight, et al.

    Background: The benefits of the early detection of the neurodegenerative and vascular pathologies which cause dementia are widely acknowledged. These include the opportunity to initiate risk‐reduction strategies, disease‐modifying therapies, and future care planning. However, current pathological biomarkers have several important drawbacks, as they are typically invasive, expensive, impractical, insensitive, or lack real‐world validation. Conversely, the targeted utilization of non‐invasive and inexpensive digital technologies which can be integrated into everyday life raises the possibility of capturing a ‘digital‐fingerprint’ of early disease.Method: The Early Detection of Neurodegenerative diseases (EDoN) initiative is a meta‐cohort study spearheaded by Alzheimer’s Research UK. EDoN is acquiring high‐dimensional data from a ‘digital toolkit’ comprising a smartwatch (Fitbit Charge 4/5), smartphone software (Mezurio and Longevity), and an electroencephalography headband (Dreem 3). In combination with conventional digital, cognitive and biological markers, these data will inform the development of powerful machine learning models to detect dementia‐causing diseases at the very earliest stages. The initial phase, incorporating four cohorts across three continents, is already underway, and will recruit nearly 900 participants. Cohorts are recruiting healthy individuals, as well as patients with subjective/mild cognitive impairment, or established dementia. Data from version‐1 of the toolkit is being collected over two‐week periods at 3‐monthly intervals for a minimum of 12 months.Result: We will present early insights from the implementation of the EDoN digital toolkit version‐1. These will include sample characteristics, feasibility and acceptability, and participants’ compliance. PPI data confirmed good acceptability but the potential for inequity due to technical problems and poor digital literacy. Pilot data indicate that six‐month adherence to the EDoN digital tools varies between 82‐89%. The forthcoming AAIC presentation will include important recruitment, toolkit acceptability and analytic updates.Conclusion: The initial implementation of the EDoN digital toolkit suggests that it is feasible and acceptable to collect high‐dimensional digital data over a six‐month period. These ‘digital‐fingerprints’ will form the basis of the initial development of machine learning models to identify dementia‐causing pathologies substantially earlier. The insights gained will also inform the development of version‐2 of the EDoN digital toolkit which will be incorporated into the next meta‐cohort prospective study of around 4,000 participants.


  • Open Access

    Evaluating the Feasibility of Frequent Cognitive Assessment Using the Mezurio Smartphone App: Observational and Interview Study in Adults With Elevated Dementia Risk

    by Claire Lancaster, Ivan Koychev, Jasmine Blane, Amy Chinner, Leona Wolters, Chris Hinds

    Background: By enabling frequent, sensitive, and economic remote assessment, smartphones will facilitate the detection of early cognitive decline at scale. Previous studies have sustained participant engagement with remote cognitive assessment over a week; extending this to a period of 1 month clearly provides a greater opportunity for measurement. However, as study durations are increased, the need to understand how participant burden and scientific value might be optimally balanced also increases. Objective: This study explored the little but often approach to assessment employed by the Mezurio app when prompting participants to interact every day for over a month. Specifically, this study aimed to understand whether this extended duration of remote study is feasible, and which factors promote sustained participant engagement over such periods. Methods: A total of 35 adults (aged 40-59 years) with no diagnosis of cognitive impairment were prompted to interact with the Mezurio smartphone app platform for up to 36 days, completing short, daily episodic memory tasks in addition to optional executive function and language tests. A subset (n=20) of participants completed semistructured interviews focused on their experience of using the app. Results: Participants complied with 80% of the daily learning tasks scheduled for subsequent tests of episodic memory, with 88% of participants still actively engaged by the final task. A thematic analysis of the participants’ experiences highlighted schedule flexibility, a clear user interface, and performance feedback as important considerations for engagement with remote digital assessment. Conclusions: Despite the extended study duration, participants demonstrated high compliance with the schedule of daily learning tasks and were extremely positive about their experiences. Long durations of remote digital interaction are therefore definitely feasible but only when careful attention is paid to the design of the users’ experience.


  • Open Access

    The True Colours Remote Symptom Monitoring System: A Decade of Evolution

    by Sarah M Goodday, Lauren Atkinson, Guy Goodwin, Kate Saunders, Matthew South, Clare Mackay, Mike Denis, Chris Hinds, Mary-Jane Attenburrow, Jim Davies, et al.

    The True Colours remote mood monitoring system was developed over a decade ago by researchers, psychiatrists, and software engineers at the University of Oxford to allow patients to report on a range of symptoms via text messages, Web interfaces, or mobile phone apps. The system has evolved to encompass a wide range of measures, including psychiatric symptoms, quality of life, and medication. Patients are prompted to provide data according to an agreed personal schedule: weekly, daily, or at specific times during the day. The system has been applied across a number of different populations, for the reporting of mood, anxiety, substance use, eating and personality disorders, psychosis, self-harm, and inflammatory bowel disease, and it has shown good compliance. Over the past decade, there have been over 36,000 registered True Colours patients and participants in the United Kingdom, with more than 20 deployments of the system supporting clinical service and research delivery. The system has been adopted for routine clinical care in mental health services, supporting more than 3000 adult patients in secondary care, and 27,263 adolescent patients are currently registered within Oxfordshire and Buckinghamshire. The system has also proven to be an invaluable scientific resource as a platform for research into mood instability and as an electronic outcome measure in randomized controlled trials. This paper aimed to report on the existing applications of the system, setting out lessons learned, and to discuss the implications for tailored symptom monitoring, as well as the barriers to implementation at a larger scale.


  • Open Access

    Evaluating the Feasibility of Frequent Cognitive Assessment Using the Mezurio Smartphone App: Observational and Interview Study in Adults With Elevated Dementia Risk (Preprint)

    by Claire Lancaster, Ivan Koychev, Jasmine Blane, Amy Chinner, Leona Wolters, Chris Hinds

    BACKGROUND By enabling frequent, sensitive, and economic remote assessment, smartphones will facilitate the detection of early cognitive decline at scale. Previous studies have sustained participant engagement with remote cognitive assessment over a week; extending this to a period of 1 month clearly provides a greater opportunity for measurement. However, as study durations are increased, the need to understand how participant burden and scientific value might be optimally balanced also increases. OBJECTIVE This study explored the little but often approach to assessment employed by the Mezurio app when prompting participants to interact every day for over a month. Specifically, this study aimed to understand whether this extended duration of remote study is feasible, and which factors promote sustained participant engagement over such periods. METHODS A total of 35 adults (aged 40-59 years) with no diagnosis of cognitive impairment were prompted to interact with the Mezurio smartphone app platform for up to 36 days, completing short, daily episodic memory tasks in addition to optional executive function and language tests. A subset (n=20) of participants completed semistructured interviews focused on their experience of using the app. RESULTS Participants complied with 80% of the daily learning tasks scheduled for subsequent tests of episodic memory, with 88% of participants still actively engaged by the final task. A thematic analysis of the participants’ experiences highlighted schedule flexibility, a clear user interface, and performance feedback as important considerations for engagement with remote digital assessment. CONCLUSIONS Despite the extended study duration, participants demonstrated high compliance with the schedule of daily learning tasks and were extremely positive about their experiences. Long durations of remote digital interaction are therefore definitely feasible but only when careful attention is paid to the design of the users’ experience.


  • Open Access

    The True Colours Remote Symptom Monitoring System: A Decade of Evolution (Preprint)

    by Sarah M Goodday, Lauren Atkinson, Guy Goodwin, Kate Saunders, Matthew South, Clare Mackay, Mike Denis, Chris Hinds, Mary-Jane Attenburrow, Jim Davies, et al.

    UNSTRUCTURED The True Colours remote mood monitoring system was developed over a decade ago by researchers, psychiatrists, and software engineers at the University of Oxford to allow patients to report on a range of symptoms via text messages, Web interfaces, or mobile phone apps. The system has evolved to encompass a wide range of measures, including psychiatric symptoms, quality of life, and medication. Patients are prompted to provide data according to an agreed personal schedule: weekly, daily, or at specific times during the day. The system has been applied across a number of different populations, for the reporting of mood, anxiety, substance use, eating and personality disorders, psychosis, self-harm, and inflammatory bowel disease, and it has shown good compliance. Over the past decade, there have been over 36,000 registered True Colours patients and participants in the United Kingdom, with more than 20 deployments of the system supporting clinical service and research delivery. The system has been adopted for routine clinical care in mental health services, supporting more than 3000 adult patients in secondary care, and 27,263 adolescent patients are currently registered within Oxfordshire and Buckinghamshire. The system has also proven to be an invaluable scientific resource as a platform for research into mood instability and as an electronic outcome measure in randomized controlled trials. This paper aimed to report on the existing applications of the system, setting out lessons learned, and to discuss the implications for tailored symptom monitoring, as well as the barriers to implementation at a larger scale.